The use of enteral feeding tubes to administer antiretroviral medications is necessary in certain patients with human immunodeficiency virus (HIV) infection. However, adequacy of drug exposures after these administration routes are largely unknown, making dosing recommendations and the attainment of viral suppression challenging in this patient population. This report describes a patient with advanced HIV infection and a complicated medical history including long-term intractable nausea/ vomiting necessitating antiretroviral medication administration via a Roux-en-Y jejunostomy (J)-tube. Pharmacokinetic assessments were performed to compare differences in antiretroviral drug absorption and plasma exposure following oral and J-tube administration of dolutegravir, tenofovir disoproxil fumarate, and emtricitabine. Results were also compared with published pharmacokinetic data in HIVinfected individuals. Exposure to dolutegravir and tenofovir were similar between J-tube and oral administration routes, whereas emtricitabine exposure was 38% lower when administered via J-tube. However, in comparison with reference data in HIV-infected individuals taking these medications orally, exposure to dolutegravir and tenofovir was 75-76% and 55-61% lower, respectively, following both routes of administration. Emtricitabine exposure was similar to and 71% higher than reference data following J-tube and oral administration, respectively. This report highlights the importance of a Authors contributed equally to this work.
The use of enteral feeding tubes to administer antiretroviral medications is necessary in certain patients with human immunodeficiency virus (HIV) infection. However, adequacy of drug exposures after these administration routes are largely unknown, making dosing recommendations and the attainment of viral suppression challenging in this patient population. This report describes a patient with advanced HIV infection and a complicated medical history including long-term intractable nausea/ vomiting necessitating antiretroviral medication administration via a Roux-en-Y jejunostomy (J)-tube. Pharmacokinetic assessments were performed to compare differences in antiretroviral drug absorption and plasma exposure following oral and J-tube administration of dolutegravir, tenofovir disoproxil fumarate, and emtricitabine. Results were also compared with published pharmacokinetic data in HIVinfected individuals. Exposure to dolutegravir and tenofovir were similar between J-tube and oral administration routes, whereas emtricitabine exposure was 38% lower when administered via J-tube. However, in comparison with reference data in HIV-infected individuals taking these medications orally, exposure to dolutegravir and tenofovir was 75-76% and 55-61% lower, respectively, following both routes of administration. Emtricitabine exposure was similar to and 71% higher than reference data following J-tube and oral administration, respectively. This report highlights the importance of performing pharmacokinetic assessments in patients with the potential for impaired drug absorption to ensure antiretroviral treatment success. KEY WORDS antiretroviral, dolutegravir, emtricitabine, HIV, J-tube, pharmacokinetics, tenofovir disoproxil fumarate, therapeutic drug monitoring. (Pharmacotherapy 2017;37 (8) :e82-e89) doi: 10.1002/phar.1960
The use of enteral feeding tubes for medication administration is necessary in some patients. However, data comparing medication absorption and subsequent drug exposures between oral and enteral feeding tube routes are limited. Drug absorption may be altered when administered through an enteral feeding tube due to the physicochemical properties and formulation of the drug, the need to crush tablets, and the physical characteristics of the gastrointestinal (GI) region into which drugs are being administered. 1 Specifically, direct medication administration into the jejunum may alter drug absorption for a number of reasons related to bypassing the stomach and duodenum including less absorptive surface area, differences in pH and subsequent drug ionization, 2 and the variable presence of drug-metabolizing enzymes and efflux transporters along the small intestine. 3, 4 For antiretroviral therapy, adequate drug exposure is critical to achieving and maintaining virologic suppression of human immunodeficiency virus (HIV). Subtherapeutic antiretroviral concentrations may result in virologic failure, disease progression, and/or the development of drug resistance. We report on pharmacokinetic (PK) assessments performed following oral and jejunostomy (J)-tube administration of the antiretroviral medications dolutegravir, tenofovir disoproxil fumarate (DF), and emtricitabine in a patient with advanced HIV infection and a Roux-en-Y jejunostomy.
Case Report
The patient was a 47-year-old African-American man diagnosed with HIV in 1999. He was nonadherent to his HIV care and received antiretroviral treatment intermittently until 2007, when he presented with complaints of intractable nausea/vomiting, a CD4 T-cell count of 13 cells/mm 3 , and plasma HIV-1 RNA (viral load [HIV-VL]) above 750,000 copies/ml. The patient was diagnosed with disseminated Mycobacterium avium complex infection and began appropriate treatment. However, his symptoms of nausea/vomiting persisted.
Since 2007, the patient's medical history was significant for recurrent pneumonias (including Pneumocystis), herpes zoster, Clostridium difficile-associated diarrhea, azole-and echinocandin-resistant Candida esophagitis, anemia, reactive airway disease requiring home oxygen, and medication nonadherence related to decreased appetite, nausea/vomiting, and depression. A J-tube was inserted in 2008 for medication administration in the setting of persistent and intractable nausea/vomiting. This was revised in 2012 via a Roux-en-Y jejunojejunostomy with new J-tube insertion and partial small bowel resection. Between 2013 and 2016, the patient continued to experience nausea/vomiting with no identified etiology, and his weight declined from 133 to 59 kg for a total weight loss of 74 kg. Multiple computed tomography scans of the abdomen performed in 2016 could not identify any etiologies to explain his symptoms, and no gross anatomic abnormalities were found.
In September 2016, the patient was referred to the National Institutes of Health (NIH) for enrollment in a protocol to manage patients with antiretroviral treatment failure (ClinicalTrials. gov NCT01976715). This study was reviewed and approved by the National Cancer Institute's institutional review board. At enrollment, his CD4 count was 8 cells/mm 3 and HIV-VL was 20,365 copies/ml. His virus had multiple resistance mutations to nucleoside and nonnucleoside reverse transcriptase inhibitors and protease inhibitors, but no documented resistance mutations to integrase strand transfer inhibitors (Table 1) . 5 Figure 1 details his antiretroviral treatment history since 2007, with his most recent regimen consisting of once/day dolutegravir 50 mg with coformulated tenofovir DF 300 mg/emtricitabine 200 mg. He was not taking any prescription or over-the-counter medications known to interact with his antiretroviral medications.
The patient was previously advised by an outside provider to take his antiretroviral medications orally instead of by J-tube to enhance absorption. However, this resulted in significant nausea/vomiting up to 3-4 times/week and persistent nonadherence. As part of the study protocol, the patient was admitted to the hospital for 7 days to receive his antiretroviral drugs under directly observed therapy (DOT) to assess the virologic efficacy of his prescribed antiretroviral therapy. During this inpatient admission, PK assessments with HIV-VL monitoring were performed following both J-tube and oral administration. These were conducted to determine whether impaired absorption of his antiretroviral medications was responsible for his virologic failure, and to compare antiretroviral drug exposure following each route of administration. HIV-VLs were collected on days 1, 3, 5, and 8 of the admission. The PK assessments are further detailed under the Methods and Results sections.
The patient did not experience any nausea/ vomiting following antiretroviral medication administration throughout the inpatient admission and tolerated his antiretroviral therapy well. The patient's HIV-VL declined from 37,620 copies/ml on day 1 to 1011 copies/ml on day 8, a 1.57 log 10 decline. At his week 2 protocol visit after the DOT admission, the patient reported nausea/vomiting since discharge. He underwent another J-tube replacement in the interim and subsequently experienced worsening abdominal pain, with weight loss of another 7 kg. He also reported missing doses of his antiretroviral medications subsequent to these symptoms, resulting in a rebound of his HIV-VL to 15,530 copies/ml. Shortly thereafter, he had a 10-day admission at an outside hospital for severe abdominal pain, dehydration, and possible pneumonia. His J-tube was evaluated and determined to be patent. He returned to the NIH after discharge from the outside hospital, which was 5 weeks after his DOT visit, and reported ongoing abdominal pain with nausea/vomiting in addition to poor medication adherence. His HIV-VL had further increased to 55,984 copies/ml. Because he was not tolerating any medications, further adjustments to his antiretroviral regimen were not possible at that time. One week later, he presented to an emergency department with severe abdominal pain and hypotension. An emergency exploratory laparotomy was performed, and it was noted that part of his small bowel had twisted around his J-tube. Immediately postsurgery, he had a myocardial infarction and cardiac arrest. The patient died 10 days after surgery.
Methods
During the 7-day inpatient DOT admission, after breakfast, dolutegravir 50 mg (Tivicay, ViiV Healthcare, Research Triangle Park, NC) and the fixed-dose combination tablet of tenofovir DF 300 mg/emtricitabine 200 mg (Truvada, Gilead, Foster City, CA) were administered via J-tube on days 1-3, orally on day 4, and then J-tube administration was resumed. Medications administered via J-tube were crushed, mixed with 3-5 ml water, given immediately, and flushed with~10 ml water. The patient was premedicated with ondansetron before administration of his oral antiretroviral medications on day 4, and his antiretroviral medications were given as intact tablets.
Blood was collected for PK analysis at time 0 (predose), 1, 2, 4, and 24 hours postdose on days 3 (J-tube administration) and 4 (oral administration). Samples were centrifuged at 1973 g for 10 minutes at 4°C after collection, stored at À80°C, and then shipped on dry ice to the University of North Carolina Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core (Chapel Hill, NC) for further analysis. Dolutegravir, tenofovir, and emtricitabine plasma concentrations were measured using standard protein precipitation followed by liquid chromatography and tandem mass spectrometry analysis. Isotopically labeled dolutegravir-13 C,d 5 ; tenofovir-13 C; and emtricitabine- 13 C, 15 N were used as internal standards, resulting in analyte calibration ranges of 50-10,000 ng/ml for dolutegravir; 1-4000 ng/ml for tenofovir; and 50-4000 ng/ml for emtricitabine. Precision and accuracy of calibration standards and quality controls were within 15% (20% at the lower limit of quantitation).
Drug concentrations following both administration routes were plotted and compared against oral reference PK data in HIV-infected individuals that were digitized from published reports (Graph Digitizer v.2.0). [6] [7] [8] Area under the concentration-time curve (AUC) was calculated based on exact time after dose rather than nominal time using noncompartmental analysis with linear-up/log-down trapezoidal rule (Phoenix WinNonlin v.6.3, Certara USA, Inc., Princeton, NJ). Maximum concentration (C max ) and concentration at the end-of-the-dosing-interval (C s ) were based on direct observation of measured data. Figure 2 and Table 2 . When comparing dolutegravir and tenofovir exposures between J-tube and oral administration, the AUCs for each drug were similar between administration routes. Dolutegravir and tenofovir C max were 26% and 21% higher, respectively, with J-tube administration in comparison with oral. However, when compared with reference PK data in HIV-infected patients, 6 , 7 the overall exposures to dolutegravir and tenofovir were 75-76% and 55-61% lower, respectively, following both administration routes. The AUC of emtricitabine was 38% lower when given by J-tube in comparison with oral administration. However, emtricitabine exposure following J-tube administration was comparable with reference data in HIV-infected patients, and it was 71% higher when given orally. 8 C s was comparable between administration routes for all antiretroviral medications, but dolutegravir and tenofovir C s values were 71-78% and 42-43% lower than reference data, respectively. Elimination rates for both dolutegravir and tenofovir were similar to reference PK data. The terminal elimination phase for emtricitabine could not be determined.
Results

PK results are detailed in
Discussion
To our knowledge, this is the first report comparing the PK differences of these three antiretroviral agents when administered orally or via J-tube. PK assessments were performed in this patient to assess whether impaired drug absorption was contributing to his antiretroviral treatment failure, and to identify which administration route would provide optimal antiretroviral drug exposure.
The PK results revealed a number of findings. Most notably, dolutegravir and tenofovir exposures were 74-75% and 55-61% lower, respectively, following both oral and J-tube administration compared with reference PK data in HIV-infected individuals. 6, 7 Elimination rates for both dolutegravir and tenofovir were consistent with reference PK data, suggesting that reduced absorption was the primary cause for decreased drug exposure. The AUC of emtricitabine was comparable or higher than HIV-infected individuals following both administration routes. 8 Despite the lower exposure to dolutegravir and tenofovir, a 1.57 log 10 decline in the patient's HIV-VL was observed between day 1 and 8 of the DOT period, indicating effectiveness of his prescribed regimen when given daily by DOT, and confirming that nonadherence was a key reason for his virologic failure.
No published data have demonstrated whether dolutegravir and tenofovir DF have altered absorption when administered via J-tube, although these data are available for several other drugs. 9 Neither dolutegravir nor tenofovir DF undergo significant first-pass metabolism by cytochrome P450 enzymes. Dolutegravir is highly permeable across the GI tract 10 and its absorption is not acid dependent, 11 although it is poorly soluble in aqueous solutions at low pH levels. The absorption site of tenofovir DF is not well characterized, 12 but its solubility is increased in acidic solutions, suggesting the proximal region of the small intestine is the most likely site of absorption. 13 The bioavailability of tenofovir DF is only~25%, thus even small alterations in absorption could have a significant impact on overall drug exposure. 14 Because of its high permeability and solubility, emtricitabine is highly bioavailable (~93%), possibly rendering it less susceptible to altered absorption following J-tube administration. 8, 13 In addition, the apparent differences in emtricitabine exposure by administration route observed in this patient may be partly due to extrapolation of the elimination phase between 4 and 24 hours. Emtricitabine PK typically follows a multicompartment model that was not captured with the selected sampling time points. Collection of additional time points between 4 and 24 hours was not feasible due to the patient's underlying anemia. However, selection of multiple time points between 0 and 4 hours allowed for adequate characterization of the patient's drug absorption following both administration routes.
Crushing of dolutegravir and tenofovir DF for oral or enteral feeding tube administration has previously been detailed. Oral administration of crushed dolutegravir (with abacavir/lamivudine) in healthy volunteers increases C max and AUC by 29% and 26%, respectively, compared with intact tablet. 15 In a separate case report, crushed twice/day dolutegravir with rilpivirine administered via orogastric tube resulted in levels below reported therapeutic ranges for these agents, although virologic suppression was maintained. 16 For tenofovir DF, one case report demonstrated its absorption was not altered when administered via gastrostomy tube. 17 Although helpful for comparison, these results are not directly applicable to our patient because he received his antiretroviral medications via Jtube. Furthermore, marked decreases in dolutegravir and tenofovir exposure were identified in comparison with reference PK, even following oral administration of intact tablet in our patient.
The exact mechanism for this patient's decreased dolutegravir and tenofovir DF absorption following oral administration remains unclear. Available records since 2007 did not detail significant surgical resection of his GI tract or a clear etiology for the patient's persistent nausea/vomiting and abdominal pain. A surgical resection performed in 2012 was deemed minor according to available surgical notes, and a short segment of the jejunum (~45 cm) was connected to the abdominal wall for the revised J-tube insertion. Thus most of the patient's small intestine remained intact following this procedure. Work-up for physiologic and infectious etiologies since the 2012 procedure was unrevealing. Dolutegravir absorption can be reduced if coadministered with agents containing polyvalent cation. 11 However, the patient was not taking any of these interacting medications. Given the patient's long history of nausea/vomiting, in addition to multiple GI surgeries, the overall integrity, function, and motility of his digestive tract may have been compromised. HIV infection itself, particularly during active viral replication and with advanced disease, can contribute to malabsorption, 12 impact barrier function, 18 alter expression of drug-metabolizing enzymes and uptake/efflux transporters along the intestinal tract, 19 and cause hypochlorhydria 20 that collectively could impact antiretroviral medication absorption.
Although dolutegravir exposure was~75% lower than reference PK data following both administration routes in this patient, C s remained above the protein-adjusted 90% inhibitory concentration of 64 ng/ml for wild-type HIV. However, dolutegravir concentrations were expected to fall below 64 ng/ml between 31 and 32 hours postdose using extrapolations from this patient's data, making adherence critical. Cumulative data from dolutegravir efficacy studies in treatment-experienced patients have shown lower response rates with median C s values of 260 ng/ml, 10 and 300 ng/ml was identified as a lower effect bound at which point twice/day dolutegravir should be considered. 21 In this patient, both administration routes resulted in C s values below these thresholds. With regard to tenofovir, tenofovir DF is metabolized to tenofovir in the GI tract and plasma, and then taken into target lymphoid cells where it is converted to the active moiety, tenofovir-diphosphate. 22 Because tenofovir is not the active product, the clinical impact of this patient's lower plasma tenofovir exposure is uncertain. However, tenofovir-diphosphate concentrations in lymphoid Ratio of patient-specific PK parameters between J-tube administration versus population average steady-state PK data from HIV-infected individuals given the same oral dose of antiretroviral medications. 6-8 d Ratio of patient-specific PK parameters between oral administration versus population average steady-state PK data from HIV-infected individuals given the same oral dose of antiretroviral medication. [6] [7] [8] cells do increase with increasing plasma tenofovir exposure. 23 Despite the observed virologic response during the patient's 7-day inpatient DOT visit, there was concern for continuing the patient on the same antiretroviral regimen and doses given his low dolutegravir and tenofovir exposures, especially with his cumulative antiretroviral drug resistance mutations and poor medication adherence history. Multiple options were considered that included increasing the dolutegravir dose to 50 mg twice/day or 100 mg once/day with follow-up PK monitoring because dolutegravir does not demonstrate dose proportionality, 10 or switching from dolutegravir to cobicistat-boosted darunavir. A tenofovir-and emtricitabine-based regimen was continued due to the increased viral susceptibility of tenofovir conferred by the patient's M184V mutation, which is continuously selected for in the presence of emtricitabine. 24 Switching from tenofovir DF to tenofovir alafenamide, a newer prodrug formulation of tenofovir, was also considered. No changes to emtricitabine were to be made. Unfortunately, attempts to optimize the patient's antiretroviral regimen could not be accomplished due to his clinical deterioration and eventual death in the weeks following his DOT admission.
Conclusion
Although HIV-VL monitoring provided an indication of the effectiveness of this patient's regimen, PK analysis revealed significantly lower exposures to dolutegravir and tenofovir following both oral and J-tube administration compared with historical HIV-infected controls. The mechanism for this decreased exposure, especially following oral administration, is unclear. Therapeutic drug monitoring while the patient received DOT provided an objective means of understanding this patient's altered drug absorption and the necessity of modifying the dosing of his antiretroviral medications.
